Incyte Corp.

NASDAQ:INCY   11:31:38 AM EDT
82.16
+1.52 (+1.88%)
Products, Strategic Combinations

Incyte And Cellenkos Enter Into Global Development Collaboration Agreement For Ck0804

Published: 12/30/2020 12:45 GMT
Incyte Corp. (INCY) - Incyte and Cellenkos Enter Into Global Development Collaboration Agreement for Ck0804.
Incyte Corp - Incyte Has an Exclusive Option to Acquire Sole Rights to Ck0804.
Incyte Corp - Incyte and Cellenkos Will Evaluate Combination of Ruxolitinib and Ck0804 in Patients With Myelofibrosis.
Incyte Corp - Incyte Will Fund Study, Which Will Be Operationalized by Cellenkos.
Incyte Corp - Cellenkos Would Be Eligible to Receive a $20 Million Licensing Fee.
Incyte Corp - Cellenkos Would Be Eligible to Receive Milestones Totaling Up to $294.5 Million As Well As Tiered Royalties.